Trial site
The Third People's Hospital of Chengdu
Chengdu, Sichuan 610031, ChinaNot linked to an institution yet
- 19running trials
- 2closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 24 trials
- Phase 11 trial
- Status
- Recruiting9 trials
- Active, not recruiting5 trials
- Not yet recruiting5 trials
- Completed2 trials
- Lead sponsor
- The Third People's Hospital of Chengdu5 trials
- Janssen Research & Development, LLC4 trials
- West China Hospital3 trials
- Guangdong Association of Clinical Trials2 trials
- Beijing Anzhen Hospital1 trial
- and 6 more
Running trials
Recruiting
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
NCT07855965· Phase 2· West China Hospital· Source
Contact: Yi Yang
Recruiting
DEC003M in Prostate Cancer
NCT07657806· Phase 1· Hangzhou DAC Biotechnology Co., Ltd.· Source
Contact: Hui Zhuo, MD (Doctor of Medicine)
Recruiting
Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial
NCT07341932· Beijing Anzhen Hospital· Source
Contact: Zhen Zhang
Recruiting
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
NCT07444437· Phase 2· Suzhou BlueHorse Therapeutics Co., Ltd.· Source
Contact: Yi Yang
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Contact: Guisen Li
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698· Phase 2· Guangdong Association of Clinical Trials· Source
Contact: Yi Y Yang
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
FIH Study of PFLotus in Persistent Atrial Fibrillation
NCT07301190· The Third People's Hospital of Chengdu· Source
Contact: Shiqiang Xiong, Doctor of Medicine
Recruiting
Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices
NCT06652750· The Third People's Hospital of Chengdu· Source
Contact: Yan Luo, master of medicine
Active, not recruiting
Using a Novel Balloon-shaped Large-Focal Pulsed Field Ablation Catheter in Persistent Atrial Fibrillation
NCT07294742· The Third People's Hospital of Chengdu· Source
Not yet recruiting
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274· Guangdong Association of Clinical Trials· Source
Contact: Yi Yang, MD
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252· Tang-Du Hospital· Source
Contact: Yingxin Wu, Master
Active, not recruiting
FIH of PFBalloon for PVI
NCT07320976· The Third People's Hospital of Chengdu· Source
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
NCT06242418· Phase 2· West China Hospital· Source
Contact: Zhang Yuanchuan
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
NCT04922853· Phase 3· West China Hospital· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error